Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best stocks under $5 with huge upside potential. Chardan reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on April 10, setting a $16 price target on the stock. The rating update came after Replimune received a second complete response letter from the FDA for RP1 in combination with nivolumab in adults with unresectable advanced cutaneous melanoma who had progressed after anti-PD-1 therapy. The firm told investors in a research note that it sees the CRL as a positive factor for the company’s Amtagvi’s near-term competitive position in post-checkpoint melanoma. However, it also added that more direct competition from cell therapies “could be on the horizon” in 2027.
For additional reference, Iovance Biotherapeutics, Inc. reported a 30% quarterly revenue growth in its fiscal Q4 and full year 2025 results, driven by Amtagvi demand. Management also reported that gross margin rose to 50%, while fiscal year 2025 revenue of $264 million attained annual guidance.
Iovance Biotherapeutics is a biopharmaceutical company that develops and commercializes cell therapies as novel cancer immunotherapy products. The company’s lead product candidate is LN-144, which is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for metastatic melanoma.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
